DrugId:  1
1. Name:  Amatuximab
2. Groups:  Investigational
3. Description:  Amatuximab has been used in trials studying the treatment and basic science of Mesothelioma, Ovarian Cancer, Ovarian Neoplasms, Pancreatic Cancer, and Mesothelioma, Malignant, among others.
4. Indication:  Not Available
DrugId:  2
1. Name:  APR-246
2. Groups:  Investigational
3. Description:  APR-246 has been used in trials studying the treatment of Prostatic Neoplasms, Hematologic Neoplasms, and Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53.
4. Indication:  Not Available
DrugId:  3
1. Name:  CP-547632
2. Groups:  Investigational
3. Description:  CP-547632 has been used in trials studying the treatment of Ovarian Cancer, Lung Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms, and Fallopian Tube Cancer, among others.
4. Indication:  Not Available
DrugId:  4
1. Name:  Berzosertib
2. Groups:  Investigational
3. Description:  Berzosertib (VX-970) has been used in trials studying the treatment of Ovarian Neoplasms, Ovarian Serous Tumor, Adult Solid Neoplasm, Advanced Solid Tumor, and Advanced Solid Neoplasm, among others.
4. Indication:  Not Available
DrugId:  5
1. Name:  9-aminocamptothecin
2. Groups:  Investigational
3. Description:  Aminocamptothecin has been used in trials studying the treatment of Lymphoma, Gastric Cancer, Ovarian Cancer, Esophageal Cancer, and Ovarian Neoplasms, among others.
4. Indication:  Not Available
DrugId:  6
1. Name:  CPG-52852
2. Groups:  Investigational
3. Description:  852A has been used in trials studying the treatment of Melanoma, Neoplasms, Breast Cancer, Ovarian Cancer, and Cervical Cancer, among others.
4. Indication:  Not Available
DrugId:  7
1. Name:  MK-1775
2. Groups:  Investigational
3. Description:  MK-1775 has been used in trials studying the treatment of LYMPHOMA, Neoplasms, Ovarian Cancer, Tongue Carcinoma, and Adult Glioblastoma, among others.
4. Indication:  Not Available
DrugId:  8
1. Name:  LCL-161
2. Groups:  Investigational
3. Description:  LCL161 has been used in trials studying the treatment of Leukemia, Neoplasms, Solid Tumors, Breast Cancer, and Ovarian Cancer, among others.
4. Indication:  Not Available
DrugId:  9
1. Name:  Pertuzumab
2. Groups:  Approved
3. Description:  Pertuzumab is a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (Subdomain II) of the human epidermal growth factor receptor 2 protein (HER2). It consists of two heavy chains and two lights chains that have 448 and 214 residues respectively. FDA approved June 8, 2012.
4. Indication:  Pertuzumab is indicated for use in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
DrugId:  10
1. Name:  Mirostipen
2. Groups:  Investigational
3. Description:  Not Available
4. Indication:  Investigated for use/treatment in breast cancer, lung cancer, and ovarian cancer.
DrugId:  11
1. Name:  BCG vaccine
2. Groups:  Investigational
3. Description:  BCG vaccine has been investigated for the treatment of Neoplasms, Bladder Cancer, Neoplasms by Site, Urologic Diseases, and Urologic Neoplasms, among others.
4. Indication:  Not Available
DrugId:  12
1. Name:  Enfortumab vedotin
2. Groups:  Investigational
3. Description:  Enfortumab vedotin has been used in trials studying the treatment of Tumors, Neoplasms, and Medical Oncology.
4. Indication:  Not Available
DrugId:  13
1. Name:  Farletuzumab
2. Groups:  Investigational
3. Description:  Farletuzumab (MORAb-003) is a fully humanized monoclonal antibody against the folate receptor alpha, for the potential treatment of epithelial ovarian cancer.
4. Indication:  Investigated for use/treatment in ovarian cancer.
DrugId:  14
1. Name:  Patritumab
2. Groups:  Investigational
3. Description:  Patritumab has been used in trials studying the treatment of LUNG CANCER, Solid Tumors, Neoplasms by Site, Head and Neck Neoplasms, and Non-small Cell Lung Cancer, among others.
4. Indication:  Not Available
DrugId:  15
1. Name:  IDM-1
2. Groups:  Investigational
3. Description:  IDM-1 is IDMâ€™s most advanced antibody-based Cell drug for the treatment of cancer. It is comprised of MAK(Monocytes-derived Activated Killer) cells associated with MDX-210, a bispecific anti-HER-2/neu antibody developed by Medarex Inc.
4. Indication:  Ovarian cancer
DrugId:  16
1. Name:  5-fluoro-2'-deoxycytidine
2. Groups:  Investigational
3. Description:  5-fluoro-2'-deoxycytidine has been used in trials studying the treatment of Neoplasms, Lung Neoplasms, Breast Neoplasms, Head and Neck Neoplasms, and Urinary Bladder Neoplasms, among others.
4. Indication:  Not Available
DrugId:  17
1. Name:  Lumretuzumab
2. Groups:  Investigational
3. Description:  Lumretuzumab has been used in trials studying the treatment of Neoplasms, Breast Cancer, Squamous Non-Small Cell Lung Cancer, and Non-Squamous Non-Small Cell Lung Cancer.
4. Indication:  Not Available
DrugId:  18
1. Name:  IGN301
2. Groups:  Investigational
3. Description:  IGN301 is a cancer vaccine based on an anti-idiotypic antibody which provokes an immune response to Lewis Y. Lewis Y is a carbohydrate molecule expressed on the surface of tumor cells of epithelial origin (e.g. lung, intestinal, breast, prostate or ovarian cancers).
4. Indication:  Investigated for use/treatment in cancer/tumors (unspecified).
DrugId:  19
1. Name:  Figitumumab
2. Groups:  Investigational
3. Description:  Figitumumab has been used in trials studying the treatment of Sarcoma, Solid Tumor, Breast Cancer, Lung Neoplasms, and Advanced Cancer, among others.
4. Indication:  Not Available
DrugId:  20
1. Name:  Ganitumab
2. Groups:  Investigational
3. Description:  Ganitumab has been used in trials studying the treatment of Colon Cancer, Rectal Cancer, Breast Cancer, Breast Tumors, and Breast Neoplasms, among others.
4. Indication:  Not Available
DrugId:  21
1. Name:  Onartuzumab
2. Groups:  Investigational
3. Description:  Onartuzumab has been used in trials studying the treatment of Neoplasms, Lung Cancer, Glioblastoma, Gastric Cancer, and Colorectal Cancer, among others.
4. Indication:  Not Available
DrugId:  22
1. Name:  Duligotuzumab
2. Groups:  Investigational
3. Description:  Duligotuzumab has been used in trials studying the treatment of Neoplasms, Colorectal Cancer, Head and Neck Cancer, and Epithelial Tumors, Malignant.
4. Indication:  Not Available
DrugId:  23
1. Name:  Ascrinvacumab
2. Groups:  Investigational
3. Description:  Ascrinvacumab has been used in trials studying the treatment and basic science of Neoplasms, Advanced Solid Tumors, Carcinoma, Hepatocellular, and Malignant Pleural Mesothelioma.
4. Indication:  Not Available
DrugId:  24
1. Name:  PRLX 93936
2. Groups:  Investigational
3. Description:  PRLX 93936 is selectively toxic to cancer cells.
4. Indication:  Investigated for use/treatment in solid tumors.
DrugId:  25
1. Name:  Lorvotuzumab mertansine
2. Groups:  Investigational
3. Description:  Lorvotuzumab mertansine has been used in trials studying the treatment of SCLC, Leukemia, Ovarian Cancer, Multiple Myeloma, and Merkel Cell Carcinoma, among others.
4. Indication:  Not Available
